Červenec 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics a GenScript ProBio jsou v procesu podepisování smlouvy na vývoj a výrobu plazmidových a virových vektorů pro první potrubí platformy Advanced CAR-T (platforma ACT) společnosti ACT Therapeutics, která bude rovněž pověřena výrobou surovin. pro následné potrubí ACT Therapeutics. Smlouva bude pokrývat produkci plazmidů a virových vektorů pro první potrubí platformy Advanced CAR-T společnosti ACT Therapeutics.
V důsledku této dohody byl GenScript ProBio povýšen na globálního partnera, který je schopen podporovat platformy ACT pro ACT terapeutika.
Platforma ACT je technologie buněčné a genové terapie nové generace, která se zaměřuje na rakovinné antigeny vložením genů určených k zacílení těchto antigenů do imunitních buněk. Tyto geny jsou dodávány do imunitních buněk pomocí virových vektorů. GenScript ProBio disponuje vysoce kvalitním vývojem virových vektorových procesů a platformou komplexních služeb pro produkci GMP, které jsou oba nezbytné pro vývoj buněčné a genové terapie.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing rakovina krve. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, generální ředitel ACT Therapeutics, řekl: „Dokončili jsme přípravy na to, aby se platforma ACT objevila globálně prostřednictvím strategického partnerství s GenScript ProBio. Urychlíme vývoj léčby zaměřené na refrakterní a neléčitelné solidní rakoviny.“
O GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
K poslání „Inovace prostřednictvím spolupráce“ se GenScript ProBio zavázal pomáhat zákazníkům zkrátit časovou osu pro vývoj biologických léků od objevu až po komercializaci, výrazně snížit náklady na výzkum a vývoj a vybudovat zdravější budoucnost.
